Further, EV led to a significant reduction of tumor volume in Nectin-4 positive bladder cancer, breast cancer, and lung cancer xenografts and to a significant inhibition of tumor growth in Nectin-4 positive pancreatic cancer xenografts compared to controls. The gene discussed is NECTIN4; the disease is breast carcinoma.